Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer
      QxMD      Google Scholar   
Citation:
Am J Clin Oncol vol 33 (4) 353-357
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA052352, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35431, CA-52352, CA-35195, U10 CA037404, U10 CA063848, U10 CA035195, CA-35103, CA-25224, U10 CA035272, CA-35113, U10 CA035113, CA-63848, U10 CA063849, U10 CA035431, CA-37417, CA-35272, CA-35269, U10 CA025224, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-0027
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
small cell lung cancer, topotecan, filgastrim, phase II